What is the medical insurance payment price of ibrutinib/ibrutinib in 2024?

Ibrutinib/ibrutinib (Ibrutinib) has shown strong potential in the field of blood cancer due to its efficient and specific covalent inhibition of BTK (Bruton's tyrosine kinase). It plays a key role in the treatment of primary chronic lymphocytic leukemia (CLL) by blocking survival signals downstream of BCR and inhibiting survival-promoting cytokines, thereby inducing apoptosis of CLL cells.

This promising preclinical activity led to an early clinical trial of ibrutinib monotherapy in patients with relapsed lymphoid malignancies and subsequent Phase Ib/II studies in relapsed CLL and mantle cell lymphoma (MCL). In these and subsequent studies, ibrutinib had an excellent safety profile and profound efficacy.

As an innovative drug, the original version of ibrutinib has been launched in the Chinese market, and is widely available in capsule form under the trade name Yike/IMBRUVICA. It is worth noting that this drug has been included in the national Class B medical insurance reimbursement list, providing financial support to eligible patients. These indications include: patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and patients with Waldenström's macroglobulinemia (WM) who have received at least one prior therapy.

Among them, the common specification in China is140 mg * 90 pills per box, and the retail price may be more than 10,000 yuan. However, due to regional differences in medical insurance reimbursement ratios, the price patients need to pay after actual reimbursement will be lower. During use, please follow your doctor's instructions and drug instructions to ensure safe and effective use.